Market Overview

UPDATE: Jefferies Initiates Pluristem Therapeutics at Hold on Balanced Risk/Reward

Related PSTI
Morning Gainers for Mar. 6, 2014: PXLW, SGMO, ERII, RGSE, NAVB, PSTI
Pluristem's Phase I/II Muscle Injury Trial Meets Primary Safety & Efficacy Endpoints

Jefferies initiated coverage on Pluristem Therapeutics (NASDAQ: PSTI) with a Hold rating and a $3.50 price target.

Jefferies analyst Eun K. Yang commented, "Positives for PSTI include (1) real unmet need/large market potential in peripheral arterial disease (PAD) and (2) proprietary stem-cell technology platform & its potential for broad applicability. Challenges are (1) yet-tobe proven clinical efficacy of PLX cells; (2) Ph2 PLX-PAD data not until ~late-2014/early-2015; (3) difficult-to-treat PAD lead indication; and (4) potential clinical/regulatory hurdles for stem-cell products."

Pluristem Therapeutics closed at $3.08 on Monday.

Posted-In: JefferiesAnalyst Color Initiation Analyst Ratings

 

Related Articles (PSTI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters